Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Foralumab in Non-Active Progressive MS
NCT05029609Phase 1Withdrawn
- Sponsor
- Tiziana Life Sciences
- Start
- Oct 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, double-blind trial of foralumab in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) (4 arms), sponsored by Tiziana Life Sciences. Primary endpoint: Safety and tolerability of intranasal foralumab at 14 days. Planned start Oct 2021; status: withdrawn.
02
Drugs
foralumab
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on NCT05029609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05029609.